Suchergebnisse
Suchergebnisse:
Juniper Biologics Pte Ltd, a top science-led pharmaceutical company focused on researching, developing and commercializing novel therapies.
We are a science-led healthcare company focused on researching, developing & commercialising novel therapies. Headquartered in Singapore, we have commercial operations in China, Japan, Asia, Australia & New Zealand, Middle East & Africa. Our approach.
3. Juli 2018 · Juniper will now provide similar capabilities in the U.K. and will complement Catalent’s multi-site oral manufacturing network to provide pharmaceutical innovators with a comprehensive solution to accelerate their drug development processes.
Pipeline - Juniper Biologics. Pipeline for continuous benefit to patients. We’re working to identify more unmet medical needs and focus our research where it is needed most.
US-based drug delivery technology company Catalent has agreed to purchase all outstanding shares of specialty healthcare firm Juniper Pharmaceuticals for a total cash consideration of $139.6m, which represents $11.50 per share.
3. Juli 2018 · clinical manuacturing M&A Catalent Juniper Pharmaceuticals. Somerset, New Jersey-based CDMO Catalent is continuing its investment and expansion campaign, announcing Tuesday that it will buy...
15. Aug. 2018 · Dive Brief: Catalent announced Tuesday that it completed its deal to acquire U.K.-based Juniper Pharmaceuticals for $11.50 per share, or a total value of $130 million. The acquisition will strengthen Catalent’s offerings in formulation development, bioavailability solutions, and clinical-scale oral dose manufacturing.
